Clinical data in 2026 shows that tirzepatide generally leads to higher weight loss, with patients averaging a 20.9% reduction in body weight over 72 weeks compared to approximately 14.9% for semaglutide
However, many peptides on the market have not undergone the strict regulatory processes like those used in medications
Together, these three peptides create a comprehensive approach: upstream pituitary stimulation (IPA + CJC) combined with downstream receptor activation (IGF-LR3)
In vivo, GLP-1(9-36) reduced counter-regulatory glucagon secretion and enhanced the plasma glucose-lowering effect of exogenous insulin in mice fasted for 5-18h
Outcomes: incident diagnoses of vaginitis/vulvovaginitis, candidiasis, dyspareunia, GSM, and prescriptions for vaginal oestrogen/antifungals
Los ensayos clnicos llevados a cabo con arGLP-1 en pacientes con obesidad (o sobrepeso [IMC 27] con comorbilidades), o con DT2 y sobrepeso u obesidad, han logrado disminuciones del peso superiores a las documentadas con orlistat, as como a las observadas con antidiabticos orales como los inhibidores del cotransportador sodio glucosa tipo 2 (iSGLT2) o la metformina62